Literature DB >> 12756196

Genetic polymorphisms of CYP2C8 in Japanese population.

Miki Nakajima1, Yuto Fujiki, Kumiko Noda, Hiroki Ohtsuka, Hisashi Ohkuni, Satoru Kyo, Masaki Inoue, Yukio Kuroiwa, Tsuyoshi Yokoi.   

Abstract

CYP2C8 plays important roles in metabolizing therapeutic drugs and endogenous compounds. Although genetic polymorphisms of CYP2C8 were reported, there is little information on CYP2C8 polymorphisms in the Japanese population. In the present study, we screened for previously described polymorphisms in the coding region of this gene using polymerase chain reaction (PCR)-restriction fragment length polymorphism or allele specific-PCR analyses. Eleven polymorphisms of CYP2C8*2 (I269F), CYP2C8*3 (R139K, K399R), CYP2C8*4 (I264M), CYP2C8*5 (frameshift), T130N, E154D, N193K, K249R, L390S, P404A, and H411L have been comprehensively investigated in at least 200 Japanese individuals. A single subject was heterozygous for CYP2C8*5, and the allele frequency was calculated as 0.0025. The other single nucleotide polymorphisms (SNPs) were not found in the Japanese subjects in the present study. Thus, it appears that the frequencies of these alleles in Japanese are extremely low. In addition, concerning the SNPs of T130N, E154D, N193K, K249R, and H411L, it remains clear that these alleles exist as polymorphisms or represent sequence errors or cloning artifacts. Although several SNPs such as CYP2C8*2, CYP2C8*3, CYP2C8*4, and P404A have been reported to reduce the enzymatic activity, pharmacokinetic abnormalities of drugs metabolized by polymorphic CYP2C8 might be rare in Japanese.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12756196     DOI: 10.1124/dmd.31.6.687

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.

Authors:  I Cavaco; J Strömberg-Nörklit; A Kaneko; M I Msellem; M Dahoma; V L Ribeiro; A Bjorkman; J P Gil
Journal:  Eur J Clin Pharmacol       Date:  2005-01-27       Impact factor: 2.953

2.  Genetic polymorphisms of CYP2C8 in the Czech Republic.

Authors:  Kristina Pechandova; Helena Buzkova; Olga Matouskova; Frantisek Perlik; Ondrej Slanar
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-07

3.  Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.

Authors:  Paulo Arnaldo; Ricardo Estevão Thompson; Márcia Quinhones Lopes; Philip Noel Suffys; Adalberto Rezende Santos
Journal:  Malays J Med Sci       Date:  2013-07

Review 4.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.

Authors:  Katrijn Bogman; Mariabeth Silkey; Siew Pheng Chan; Brian Tomlinson; Cornelia Weber
Journal:  Eur J Clin Pharmacol       Date:  2010-06-12       Impact factor: 2.953

6.  The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.

Authors:  Carmen Martínez; Elena García-Martín; Gerardo Blanco; Francisco J G Gamito; José M Ladero; José A G Agúndez
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

Review 7.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Authors:  Christina L Aquilante; Mikko Niemi; Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

8.  Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.

Authors:  Mari Jiko; Ikuko Yano; Eriko Sato; Kazushige Takahashi; Hideyuki Motohashi; Satohiro Masuda; Masahiro Okuda; Noriyuki Ito; Eijiro Nakamura; Takehiko Segawa; Toshiyuki Kamoto; Osamu Ogawa; Ken-Ichi Inui
Journal:  Int J Clin Oncol       Date:  2007-08-20       Impact factor: 3.402

9.  Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

Authors:  David R Gandara; Tomoya Kawaguchi; John Crowley; James Moon; Kiyoyuki Furuse; Masaaki Kawahara; Satoshi Teramukai; Yuichiro Ohe; Kaoru Kubota; Stephen K Williamson; Oliver Gautschi; Heinz Josef Lenz; Howard L McLeod; Primo N Lara; Charles Arthur Coltman; Masahiro Fukuoka; Nagahiro Saijo; Masanori Fukushima; Philip C Mack
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

10.  A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.

Authors:  Chikako Ishikawa; Hiroshi Ozaki; Toshiaki Nakajima; Toshihiro Ishii; Saburo Kanai; Saeko Anjo; Kohji Shirai; Ituro Inoue
Journal:  J Hum Genet       Date:  2004-09-09       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.